Connecting the Dots: The Broader Applications of GLP-1s and Where We’re Headed Next

Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-5-connecting-dots-broader-applications-glp-1s-and-where-were-headed-next